Top

Published in:

01-02-2019 | Original Article

Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes

Authors: Amer M. Zeidan, Smith Giri, Michelle DeVeaux, Samir K. Ballas, Vu H. Duong

Published in: Annals of Hematology | Issue 2/2019

Abstract

The impact of iron chelation therapy (ICT) on overall survival (OS) and progression to acute myeloid leukemia (AML) in patients with iron overload and International Prognostic Scoring System low- or intermediate-risk myelodysplastic syndromes (MDS) is not well understood. We conducted a systematic review and meta-analysis of published studies of ICT in patients with MDS to better elucidate these relationships. We searched PubMed, EMBASE, Cochrane databases, and the World Health Organization Clinical Trial Registry for studies reporting the impact of ICT on OS in patients with low- or intermediate-risk MDS. Studies were examined for demographics, effect measures, and potential bias risk. Fixed and random-effects models were used to calculate adjusted OS and adjusted hazards ratio (aHR) estimates, respectively, among the different studies. Nine observational studies (four prospective and five retrospective) were identified. For patients with MDS, ICT was associated with an overall lower risk of mortality compared with no ICT (aHR 0.42; 95% confidence interval (CI) 0.28–0.62; P < 0.01); however, there was significant heterogeneity across the studies. In studies reporting progression to AML, ICT was not associated with decreased risk of progression (odds ratio 0.68; 95% CI 0.31–1.43; P < 0.030). This systematic review and meta-analysis of nine nonrandomized trials demonstrated significant reduction in risk of mortality in patients with iron overload and low- or intermediate-risk MDS treated with ICT; however, a causal relationship cannot be established. Randomized, controlled trials are needed to more definitively evaluate the relationship between ICT and survival in patients with iron overload and low- or intermediate-risk MDS.

Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29(5):516–523CrossRefPubMedPubMedCentral

Garcia-Manero G (2015) Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(9):831–841CrossRefPubMed

Nimer SD (2008) Myelodysplastic syndromes. Blood 111(10):4841–4851CrossRefPubMed

Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361(19):1872–1885CrossRefPubMed

Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G (2013) Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831–837CrossRefPubMedPubMedCentral

Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112(1):45–52CrossRefPubMed

Stahl M, Zeidan AM (2017) Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Rev Hematol 10(4):345–364CrossRefPubMed

de Ville de Goyet M, Moniotte S, Robert A, Dupont S, Vermylen C, Veyckemans F, Brichard B (2013) Iron overload in children undergoing cancer treatments. Pediatr Blood Cancer 60(12):1982–1987CrossRefPubMed

Waszczuk-Gajda A, Madry K, Machowicz R, Drozd-Sokołowska J, Stella-Hołowiecka B, Mital A, Obara A, Szmigielska-Kapłon A, Sikorska A, Subocz E, Jędrzejczak WW, Dwilewicz-Trojaczek J (2016) Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first Polish MDS-PALG registry. Adv Clin Exp Med 25(4):633–641CrossRefPubMed

10.

Sikorska K, Bernat A, Wroblewska A (2016) Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis. Hepatobiliary Pancreat Dis Int 15(5):461–479CrossRefPubMed

11.

Gammella E, Recalcati S, Rybinska I, Buratti P, Cairo G (2015) Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxidative Med Cell Longev 2015:230182CrossRef

12.

Angelucci E, Urru SA, Pilo F, Piperno A (2017) Myelodysplastic syndromes and iron chelation therapy. Mediterr J Hematol Infect Dis 9(1):e2017021CrossRefPubMedPubMedCentral

13.

Mitchell M, Gore SD, Zeidan AM (2013) Iron chelation therapy in myelodysplastic syndromes: where do we stand? Expert Rev Hematol 6(4):397–410CrossRefPubMedPubMedCentral

14.

Malcovati L (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31(suppl 3):S2–S6CrossRefPubMed

15.

Mainous AG 3rd, Gill JM, Carek PJ (2004) Elevated serum transferrin saturation and mortality. Ann Fam Med 2(2):133–138CrossRefPubMedPubMedCentral

16.

Mainous AG 3rd, Tanner RJ, Hulihan MM, Amaya M, Coates TD (2014) The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol 167(5):720–723CrossRefPubMedPubMedCentral

17.

Carreau N, Tremblay D, Savona M, Kremyanskaya M, Mascarenhas J (2016) Ironing out the details of iron overload in myelofibrosis: lessons from myelodysplastic syndromes. Blood Rev 30(5):349–356CrossRefPubMed

18.

Leitch HA, Fibach E, Rachmilewitz E (2017a) Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. Crit Rev Oncol Hematol 113:156–170CrossRefPubMed

19.

Coates TD, Wood JC (2017) How we manage iron overload in sickle cell patients. Br J Haematol 177(5):703–716CrossRefPubMedPubMedCentral

20.

Choudhry VP (2017) Thalassemia minor and major: current management. Indian J Pediatr 84(8):607–611CrossRefPubMed

21.

Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies) (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34(7):864–870CrossRefPubMed

22.

Remacha AF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G, IRON-2 Study Group (2015) Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol 94(5):779–787CrossRefPubMed

23.

Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J (2010) Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 50(1):190–199CrossRefPubMed

24.

Lyons RM, Marek BJ, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G (2014) Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res 38(2):149–154CrossRefPubMed

25.

Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM (2012) Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res 36(11):1380–1386CrossRefPubMed

26.

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R (2017b) Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol 179(1):83–97CrossRefPubMed

27.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C (2014) Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res 38(5):557–563CrossRefPubMed

28.

Langemeijer S, De Swart L, Yu G, Smith A, Crouch S, Johnston T, Fenaux P, Symeonidis A, Cermak J, Hellstrom-Lindberg E, Sanz G, Stauder R, Malcovati L, Germing U, Skov Holm M, Mittelman M, Madry K, Tatic A, Almeida A, Savic A, Park S, Beyne-Rauzy O, Itzykson R, van Marrewijk C, Bowen D, de Witte T (2016) Impact of treatment with iron chelators in lower-risk MDS patients participating in the European Leukemianet MDS (EUMDS) Registry. Blood 128:3186 Abstract. http://www.bloodjournal.org/content/128/22/3186. Accessed 5 February 2018

29.

Komrokji RS, Ali NH, Padron E, Lancet JE, List AF (2011) Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Center. Blood 118:2776 Abstract. http://www.bloodjournal.org/content/118/21/2776. Accessed 5 February 2018

30.

Zeidan AM, Pullarkat VA, Komrokji RS (2017) Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Crit Rev Oncol Hematol 117:57–66CrossRefPubMed

31.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekell P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647CrossRef

32.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed

33.

Ottawa Hospital Research Institute (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 28 April 2017

34.

Simes RJ (1987) Confronting publication bias: a cohort design for meta-analysis. Stat Med 6(1):11–29CrossRefPubMed

35.

Zeidan AM, Gore SD, Padron E, Komrokji RS (2015a) Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol 22:146–154CrossRefPubMed

36.

Zeidan AM, Komrokji RS (2013a) There’s risk, and then there’s risk: the latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep 8(4):351–360CrossRefPubMedPubMedCentral

37.

Zeidan AM, Smith BD, Komrokji RS, Gore SD (2013b) Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med 126(4):e25CrossRefPubMedPubMedCentral

38.

Lee EJ, Podoltsev N, Gore SD, Zeidan AM (2016) The evolving field of prognostication and risk stratification in MDS: recent developments and future directions. Blood Rev 30(1):1–10CrossRefPubMed

39.

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS, MDS Clinical Research Consortium (2015b) Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: is one model better? Am J Hematol 90(11):1036–1040CrossRefPubMed

40.

Abraham I, Yami MA, Yun S, Kim HJ, Vincelette ND, McBride A, MacDonald K (2017) Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: review and pooled analysis of observational studies. Leuk Res 57:104–108CrossRefPubMed

41.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A (2017) Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br J Haematol 177(5):741–750CrossRefPubMed

42.

Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, DiBella N, Garcia-Manero G (2017) Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: registry analysis at 5 years. Leuk Res 56:88–95CrossRefPubMed

43.

Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ (2015c) Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. J Comp Eff Res 4(4):327–340CrossRefPubMedPubMedCentral

44.

Steinmetz HT, Böttger I, Lathan B, Sauer A, Moorahrend E, Severin K, Germing U, Schmitz S, Gattermann N (2014) Treatment outcome of patients with myelodysplastic syndromes (MDS) in regular care: incidence of IPSS risk groups and different therapies in the German outpatient MDS registry. Blood 124:5601 Abstract. http://www.bloodjournal.org/content/124/21/5601. Accessed 5 February 2018

45.

Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N (2012) Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 36(8):1067–1070CrossRefPubMed

46.

Chan LSA, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker L, Lee CD, Lam A, Mamedov A, Wells RA (2011) Initial transfusion rate predicts survival in MDS. Blood 118:2791 Abstract. http://www.bloodjournal.org/content/118/21/2791. Accessed 5 February 2018CrossRef

47.

Hao Y, Fu AZ, Coe A, Qiu Y, Li Z, Hanna B, Tang J, Elliott BM, Paley C (2016) Clinical outcomes among patients with myelodysplastic syndromes treated with iron chelation therapy: a real world Medicare database study. Blood 128:2396 Abstract. http://www.bloodjournal.org/content/128/22/2396. Accessed 5 February 2018

48.

List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 30(17):2134–2139CrossRefPubMed

49.

Leitch HA (2011) Controversies surrounding iron chelation therapy for MDS. Blood Rev 25(1):17–31CrossRefPubMed

50.

Zeidan AM, Kharfan-Dabaja MA, Komrokji RS (2014) Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol 21(2):123–130CrossRefPubMedPubMedCentral

51.

Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD (2016a) Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol 175(5):829–840CrossRefPubMed

52.

Zeidan AM, Stahl M, Komrokji R (2016b) Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opin Emerg Drugs 21(3):283–230CrossRefPubMed

53.

Abou Zahr A, Bernabe Ramirez C, Wozney J, Prebet T, Zeidan AM (2016) New insights into the pathogenesis of MDS and the rational therapeutic opportunities. Expert Rev Hematol 9(4):377–388CrossRefPubMed

54.

Abou Zahr A, Saad Aldin E, Barbarotta L, Podoltsev N, Zeidan AM (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Rev Anticancer Ther 15(9):1019–1036CrossRefPubMed

55.

National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology. myelodysplastic syndromes version 1.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed October 16, 2018

56.

Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, Hofmann WK (2015) Updated recommendations on the management of gastrointestinal disturbances during ironchelation therapy with Deferasirox in transfusion dependent patients with myelodysplasticsyndrome—emphasis on optimized dosing schedules and new formulations. Leuk Res 39(10):1028–1033CrossRefPubMed

57.

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA (2018) Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS. Leuk Res 74:21–41CrossRefPubMed

58.

Bennett JM (2008) Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83(11):858–861CrossRefPubMed

Title: Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
Authors: Amer M. Zeidan
Smith Giri
Michelle DeVeaux
Samir K. Ballas
Vu H. Duong
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 2/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3539-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

(1-3)-β-d-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations

Validation of the Marginal Zone Lymphoma International Prognostic Index

Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma

Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page